Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1)

The summary for the Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Medical Countermeasures to Enhance Platelet Regeneration and Increase Survival Following Radiation Exposure (RC1): -Purpose. The goal of this funding opportunity announcement (FOA) is to accelerate the development of safe and effective medical products to mitigate and treat thrombocytopenia and to enhance platelet regeneration after radiation exposure from radiological and nuclear terrorist attacks. Specifically, this new initiative will support research and development of promising new approaches and medical products to enhance platelet regeneration and yield improved survival. -Among the most important medical countermeasures against acute radiation syndrome are those that will treat or mitigate its hematopoietic component. Certain radiation exposures can cause severe damage to the bone marrow, which can have dramatic effects on circulating blood cells, including platelets, neutrophils, lymphocytes, and erythrocytes,. Platelets play an essential role in hemostasis and thrombosis. As the level of circulating platelets drops below 20,000/mm3 (a condition referred to as severe thrombocytopenia ), the risk to an affected individual for catastrophic hemorrhage increases markedly. Severe thrombocytopenia is clearly a contributor to mortality following radiation exposure. Currently, there is no approved therapeutic drug in the Strategic National Stockpile for this radiation-induced complication. -Mechanism of Support. This FOA will utilize the NIH Challenge Grant (RC1) award mechanism.